In the October 2016 issue of European Pharmaceutical Review, Andrew Butcher writes about the emergence of value-based pricing, where the price is determined as a function of measurable “value” brought by the product to relevant stakeholders. He discusses the challenges of measuring value in complex health systems and the importance of understanding the market and engaging a wide group of stakeholders well before a product launches. To read the article, click the link below.
Approaching the final frontier: Are we in a golden decade of drug development for the central nervous system?
In this CRA Insights, the authors Will Foster, Kees Chamberlain, Joanne Clark, and Carl Lottig recount the recent scientific and technological advances in...